Bisphosphonate Treatment in Chronic Recurrent Multifocal Osteomyelitis - 07/03/14
, Roger C. Allen, MBBS, Margaret R. Zacharin, MBBS
Reprint requests: Dr Peter Simm, Dept of Endocrinology and Diabetes, Royal Children’s Hospital Melbourne, Flemington Road, Parkville VIC 3052, Australia.Résumé |
Objective |
To test the safety and efficacy of biphosphonates in chronic recurrent multifocal osteomyelitis (CRMO).
Study design |
Five patients with CRMO, all of whom had ongoing pain and loss of function despite conventional treatment with non-steroidal anti-inflammatory agents, were treated with pamidronate (1 mg/kg/dose with a dosing frequency of 2 to 4 monthly for a total treatment duration of 12 to 42 months).
Results |
Pain decreased after the first infusion for 4 of 5 patients, with symptomatic improvement maintained with time. Significant improvement was seen in radiological lesions for these 4 patients.
Conclusion |
Bisphosphonates appear to be a useful and safe adjunctive treatment in CRMO when simple therapies such as anti-inflammatory agents fail to control symptoms or cases in which lesion expansion continues.
Le texte complet de cet article est disponible en PDF.Abbreviations : CNO, CRMO, NSAID, SAPHO syndrome
Plan
Vol 152 - N° 4
P. 571-575 - avril 2008 Retour au numéro
Article précédent
- Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry Disease
- J. Edmond Wraith, Anna Tylki-Szymanska, Nathalie Guffon, Y. Howard Lien, Michel Tsimaratos, Ashok Vellodi, Dominique P. Germain
- Comida en Venta: After-School Advertising on Spanish-Language Television in the United States
- Darcy A. Thompson, Glenn Flores, Beth E. Ebel, Dimitri A. Christakis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?